Polyvalent immunogen

Details Polyvalent immunogen Polyvalent immunogen

2007-02-06

2007-02-06

Stucker, Jeffrey (Department: 1648)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Fusion protein or fusion polypeptide

C424S185100, C424S186100, C424S188100, C424S193100, C424S204100, C424S208100, C530S300000, C530S324000, C530S350000, C530S826000

Reexamination Certificate

active

10431596

ABSTRACT:
The present invention relates, generally, to a polyvalent immunogen and, more particularly, to a method of inducing neutralizing antibodies against HIV and to a polyvalent immunogen suitable for use in such a method.

REFERENCES:
patent: 5013548 (1991-05-01), Haynes et al.
patent: 5019387 (1991-05-01), Haynes et al.
patent: 5352576 (1994-10-01), Haynes et al.
patent: 5516632 (1996-05-01), Palker et al.
patent: 5643756 (1997-07-01), Kayman et al.
patent: 5800822 (1998-09-01), Sia et al.
patent: 5993819 (1999-11-01), Haynes et al.
patent: 6114143 (2000-09-01), Eda et al.
patent: 2001/0003646 (2001-06-01), Haynes et al.
patent: 2001/0036461 (2001-11-01), Haynes et al.
patent: 2002/0086283 (2002-07-01), Haynes et al.
patent: 2003/0147888 (2003-08-01), Haynes et al.
patent: 2004/0001851 (2004-01-01), Haynes et al.
patent: 2004/0039172 (2004-02-01), Haynes et al.
patent: 2004/0132010 (2004-07-01), Haynes et al.
patent: 2004/0197344 (2004-10-01), Haynes et al.
patent: WO 93/15750 (1993-08-01), None
patent: WO 95/29700 (1995-11-01), None
patent: WO 97/14436 (1997-04-01), None
patent: WO 01/56355 (2001-08-01), None
patent: WO 02/24149 (2002-03-01), None
patent: WO 03/039470 (2003-05-01), None
patent: WO 03/046137 (2003-06-01), None
patent: WO 2004/009785 (2004-01-01), None
patent: WO 2004/075850 (2004-09-01), None
patent: WO 2005/016952 (2005-02-01), None
U.S. Appl. No. 60/503,460 filed Sep. 17, 2003 and U.S. Appl. No. 60/604,722 filed Aug. 27, 2004 (see attached copy of PCT/US04/30397 filed Sep. 17, 2004).
U.S. Appl. No. 10/518,523 filed Dec. 21, 2004 (U.S. National Phase of WO 2004/009785 see above).
U.S. Appl. No. 10/973,977 filed Oct. 27, 2004.
U.S. Appl. No. 10/973,475 filed Oct. 27, 2004.
U.S. Appl. No. 60/625,720 filed Nov. 8, 2004.
Pang et al, “HIV-1 Env Sequence Variation in Brain Tissue or Patients with AIDS-Related Neurologic Disease”, Journal of Acquired Immune Deficiency Syndrome 4:1082-1092 (1991).
Haynes et al, HIV Vaccine Development at Duke University Medical Center, Immunologic Research 22(2-3):263-269 (2000).
Bartlett et al, “Safety and immunogenicity of an HLA-based HIV envelope polyvalent synthetic peptide immunogen”, AIDS 12(11):1291-1300 (1998).
De Berardinis et al, “Phage display of peptide epitopes from HIV-1 elicits strong cytolytic responses”, Nature Biotechology 18:873-876 (2000).
Haynes et al, “HIV type 1 V3 region primer-induced antibody suppression is overcome by administration of C4-V3 peptides as a polyvalent immunogen”, AIDS Research and Human Retroviruses 11(2):211-221 (1995).
Spicer et al, “Modification of anti-HIV antibody response and peptide solution conformations by point substitutions in chimeric gp 120 C4-V3 immunogenic peptides”, Abstracts of Papers American Chemical Society 218(1-2):MEDI 286 (1999)-XP009052973.

Affiliated with

Also associated with

Rating

Polyvalent immunogen does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Polyvalent immunogen, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polyvalent immunogen will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3889981